ERBB2 and cancer: We next evaluated the cytotoxicity of different formulations of gPTX in two HER2-overexpressing cancer cell lines, HT-29 and SK-BR-3, and in the HER2 low-expressing cancer cell line MDA-MB-231 by the MTT assay [7], [22].